Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Technology
Healthcare IT
Return to: MDBR Home | Technology | Healthcare IT

Aptar Pharma, Propeller Health to develop digital medicine platform

Published 01 June 2018

Aptar Pharma and Propeller Health have announced plans to work on a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases.

The digital medicine platform, spanning inhaled, injectable, nasal and dermal medicine delivery forms, will combine software and experiences with connected drug delivery devices to more effectively treat diseases and improve clinical outcomes for patients.

Aptar Pharma and Propeller will work together with pharmaceutical and healthcare partners to accelerate the development, manufacturing and commercialization of digital medicines for leading marketed and pipeline brands.

Digital medicines can help to personalize treatments, monitor patients in real-time, detect day-to-day changes in disease condition and increase patient adherence. Key objectives are to improve patient outcomes and help contribute to lower healthcare costs.

The collaboration brings together Aptar Pharma’s decades of expertise in device development, packaging innovation and quality manufacturing with Propeller’s platform and leading experience in digital therapeutics design and implementation.

The two companies initially partnered in 2016 to develop the world’s first fully-integrated connected metered dose inhaler (cMDI).

Aptar Pharma president Salim Haffar said: Aptar Pharma has been providing innovative drug delivery systems for nearly 50 years, helping billions of patients around the world.

“Today, we are excited to broaden our offerings as we continue this journey towards improved patient care and clinical outcomes by growing our partnership with Propeller Health, the leader in their field of digital therapeutics.”

Propeller CEO and co-founder David Van Sickle said: “Propeller draws on nearly a decade of experience pioneering digital respiratory medicines and putting them to work in healthcare organizations around the world.”

Propeller and Aptar Pharma will co-market the platform, with Propeller managing the digital services and Aptar Pharma managing the device development, manufacturing and supply chain.

In addition to expanding the partnership, Aptar Pharma has made a strategic equity investment of $10 million in Propeller Health during their latest funding round.

Source: Company Press Release